Who
Nancy Lurker
Director
Company insider
Files Form 4 as: Director, Alkermes; Director, Collegium Pharmaceutical; Executive Vice Chair, EyePoint; Director, Aquestive Therapeutics; Director, Mallinckrodt; CEO, Interpace Biosciences; Director, Auxilium Pharmaceuticals.
In numbers
- Trades disclosed
- 257
- Buys
- 10
- Sells
- 9
- Bought
- $515K
- Sold
- $3.1M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 17 Aug 2009
- Last trade
- 21 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $55K1,475 at $36.95 | filing |
| 21 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —6,142 | filing |
| 21 May 2026filed 22 May 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $55K1,475 at $36.95 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —11,538 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —11,538 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,409 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,409 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —8,741 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —8,741 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Sold | $162K4,500 at $35.97 | filing |
| 13 May 2026filed 15 May 2026 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Sold | $162K4,500 at $35.97 | filing |
| 11 Apr 2026filed 13 Apr 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —3,751 | filing |
| 11 Apr 2026filed 13 Apr 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $30K901 at $33.36 | filing |
| 11 Apr 2026filed 13 Apr 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,751 | filing |
| 11 Apr 2026filed 13 Apr 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,751 | filing |
| 11 Apr 2026filed 13 Apr 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —3,751 | filing |
| 11 Apr 2026filed 13 Apr 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $30K901 at $33.36 | filing |
News
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Jefferies Financial Group to "Hold"EYPT · tickerreport.com · 19 Oct 2026Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Has Consensus Price Target of $48.71COLL · dailypolitical.com · 13 Oct 2026Critical Review: Eyepoint Pharmaceuticals (NASDAQ:EYPT) and GSK (NYSE:GSK)EYPT · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Nancy Lurker; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.